Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China

Abstract

Despite the fact that malignancies are associated with hematological abnormalities, some clinical studies have been unable to detect such a relation. The aim of our study was to detect the prevalence of pretreatment hematologic abnormalities in patients with common solid tumors and to determine if such a profile could be used for prognostic evaluations. We identified all patients in Cancer Center of Sun Yat-sen University who were diagnosed as solid tumors (breast carcinoma, hepatocellular carcinoma, nasopharyngeal carcinoma, esophageal carcinoma, gastric cancer, cervical carcinoma, endometrial cancer, renal cell carcinoma, and non-small cell lung cancer) between January 2000 and August 2009. All subjects were investigated regarding levels of white blood cells, platelets, and hemoglobin concentration. We identified 3,180 patients with solid tumors and 285 patients with benign diseases for the final analysis. The percentages of leukocytosis, anemia, and thrombocytosis in patients with solid tumors ranged from 4.0% to 25.6%, 3.3% to 29.2%, and 2.1% to 9.7%, respectively. The multivariate Cox analysis revealed that anemia was an independent prognostic factor in patients with breast cancer (P = 0.006), hepatocellular carcinoma (P = 0.002), nasopharyngeal carcinoma (P = 0.008), and esophageal carcinoma (P = 0.001). Leukocytosis was an independent prognostic factor in patients with cervical cancer (P = 0.007). The incidence of hematological abnormalities in Chinese patients with solid tumors was relatively lower than that of the counterparts in the Western countries. A pretreatment anemia or leukocytosis can serve as a useful marker to predict outcome of patients in some of the solid tumors.

Dysregulated Hematopoiesis Caused by Mammary Cancer Is Associated with Epigenetic Changes and Hox Gene Expression in Hematopoietic Cells

“…Interestingly, patients with preexisting anemia before therapy exhibit reduced survival following treatment for breast, lung, prostate, and other cancers (4,38). Our results support the hypothesis that breast cancer patients may develop anemia concomitant with disease severity or progression, a characteristic that may impact treatment options.…”

“…Blood was analyzed on the scil Vet abc hematology analyzer (scil animal care company) or treated with NH 4 Cl to lyse RBCs before flow cytometry.…”

“…These cells facilitate tumor growth, metastasis, and immunological escape (2). Cancer is also frequently associated with perturbations in hematopoiesis manifested as disturbed myelopoiesis, leukocytosis (leukemoid reaction), cytopenia, and/or anemia, which may predict adverse patient outcome (3,4). As the nature of antitumor immune responses may hold better prognostic value than standard scoring regimes, a better understanding of tumor-induced changes to the immune response and hematopoietic system may lead to improved cancer diagnosis and treatment (5).…”

Association between Preoperational Blood Profiles and Post Operational Complications in Patients Suffering Epithelial Ovarian Cancer

“…In another study by Kim in 2011 in South chorea the impact of duration of anemia while chemotherapy was done in patient with epithelial ovarian cancer was investigated. This study was shown that if hemoglobin lesser than 10 mg/dl lasted more than 20%of chemotherapy duration was associated with lower 5 years survival [18]. Causes of anemia in cancers are different included: iron metabolism disorders, extra corpuscular hemolysis and cell catabolism due to tumor invasion, and paracrine signaling factors such as interleukin-1, tumor necrosis factor [19].…”

Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma

“…Previously, evidence has indicated that anemia is correlated with poor clinical Preoperative mean corpuscular hemoglobin affecting long-term outcomes of hepatectomized patients with hepatocellular carcinoma prognosis in several cancer types (12)(13)(14)(15). In addition, in HCC, a previous report demonstrated the prognostic impact of hemoglobin (HGB) levels prior to treatment (16). The mean corpuscular hemoglobin (MCH), which refers to a measurement of the average HGB content of each red blood cell, is another anemia associated factor, which reflects iron metabolism.…”